Anne W. Rimoin*, Neville Kisalu†, Benoit Kebela-Ilunga‡, Thibaut Mukaba†, Linda L. Wright§, Pierre Formenty¶, Nathan D. Wolfe#, Robert Loshima Shongo‡, Florimond Tshioko**, Emile Okitolonda††, Jean-Jacques Muyembe†, Robert W. Ryder‡‡, and Hermann Meyer§§
Author affiliations: *University of California, Los Angeles, California, USA; †National Institute of Biomedical Research, Kinshasa, Democratic Republic of Congo; ‡Ministry of Health, Kinshasa, Democratic Republic of Congo; §National Institutes of Health, Bethesda, Maryland, USA; ¶World Health Organization, Geneva, Switzerland; #Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA; **World Health Organization, Kinshasa, Democratic Republic of Congo; ††Kinshasa School of Public Health, Kinshasa, Democratic Republic of Congo; ‡‡University of North Carolina, Chapel Hill, North Carolina, USA; §§Bundeswehr Institute of Microbiology, Munich, Germany;
Main Article
Table 2
Age and sex distribution of patients with monkeypox or chickenpox, Democratic Republic of Congo, 2001–2004*
| Age, y |
No. cases investigated male/female, n = 134 |
MPX-positive male/female, n = 51 |
VZV-positive male/female, n = 61 |
| <4 |
12/21 |
8/7 |
3/6 |
| 5–14 |
22/19 |
12/9 |
7/8 |
| 15–24 |
17/13 |
5/7† |
10/5† |
| 25–34 |
9/8 |
2/0 |
5/6 |
| >35 |
6/7 |
1/0 |
5/6 |
| Total |
66/68 |
28/23 |
30/31 |
Main Article
Top of Page